2-(3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-diol
• 化学式: C₅₉H₉₄O₄
• 分子量: 867.4
• InChiKey: GNZHTGOWPPDWPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  17.4
• 重原子数：
  63
• 可旋转键数：
  31
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• METHOD FOR TESTING RISK OF MULTIPLE SYSTEM ATROPHY, TEST KIT, AND DRUG FOR THE TREATMENT OR PREVENTION OF MULTIPLE SYSTEM ATROPHY
  申请人：The University of Tokyo

  公开号：US20160067195A1

  公开（公告）日：2016-03-10

  An object of the present invention is to elucidate the onset mechanism of MSA through specification of a causative gene of it and further, to find a treatment method of it. The present invention provides a method for testing a multiple system atrophy risk of a test subject including a step of detecting a variant that deteriorates the biosynthesis of coenzyme Q10 in a sample collected from the test subject. Examples of the variant that deteriorates the biosynthesis of coenzyme Q10 include variants that suppress the expression or function of coenzyme Q2.